Clinical trial
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis…
NCT00249808 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00249808 |
|---|---|
| Title | A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies |
| Official title | A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Efalizumab in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Have Failed to Respond to, or Who Have a Contraindication to, or Are Intolerant to Other Systemic Therapies Including… |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Efalizumab - anti-CD11a recombinant human monoclonal antibody |
| Enrollment | 1,266 |
| Start date | Dec 13, 2004 |
| Primary completion | Jan 25, 2007 |
| Completion | Jan 25, 2007 |
| First posted | Nov 7, 2005 |
| Last update posted | Mar 20, 2018 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: